Drug Metabolism News and Research

RSS

Compound YZG-331 leverages gut microbiota to improve sleep in mouse models of insomnia

This new article publication from Acta Pharmaceutica Sinica B discusses how interactions between the investigational compound YZG-331 and the gut microbiota contribute to its sleep-promoting effects in mouse models of insomnia.

5 Nov 2026

AGA/AASLD joint guideline evaluates newer medications for primary biliary cholangitis

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) evaluates newer medications for primary biliary cholangitis (PBC), the most common cholestatic disease in adults.

22 Oct 2026

New mechanism linked to septic heart injury protection uncovered

Sepsis triggers widespread inflammation, circulatory failure and metabolic stress, and cardiac dysfunction is a common complication associated with sharply poorer outcomes.

31 Jul 2026

Gut microbes emerge as potential players in estrogen-driven cancers

A new review maps how the endocrine-microbiome axis expands the estrobolome concept, showing that gut microbes may alter estrogen recycling, produce hormone-like metabolites, and shape inflammation and tissue environments in hormone-driven cancers. Human evidence remains mostly associative, so the authors call for causal models, longitudinal multi-omics, multi-kingdom profiling, and sex-stratified studies before microbiome-guided cancer strategies enter routine care.

25 Jun 2026

New human protein atlas maps how cancer rewires the body’s tissues

Researchers created a DIA-MS atlas of 13,609 proteins across 2,856 samples from fetal, healthy adult, paired non-tumor, and tumor tissues. The resource maps tissue-specific protein patterns, cancer-associated changes, organ-specific drug-toxicity signals, and candidate therapeutic targets.

21 Jun 2026

Study: Women survive cancer more but face higher treatment toxicity

Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

17 Mar 2026

Aptamer-based wearables revolutionize continuous health tracking

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health management, yet most clinical tests rely on invasive, single-point blood sampling. Recent advances in aptamer-based wearable electrochemical sensors offer a promising alternative by enabling real-time, continuous tracking of physiological signals directly in or on the body.

30 Jan 2026

Sapio Sciences announces partner ecosystem for ELaiN, its third-generation AI lab notebook

Sapio Sciences, the science-aware™ AI lab informatics platform, today announced the availability of trusted, third-party scientific applications and platforms now integrated directly into Sapio ELaiN, its third-generation AI lab notebook.

From Sapio Sciences 16 Jan 2026

Most clinical trials fail to reflect America’s racial and ethnic diversity

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and Hispanic individuals.

12 Dec 2025

Advancing drug discovery with AI, generative chemistry, and 3D molecular design

Discover how AI, generative chemistry, and 3D molecular design are revolutionizing drug discovery.

From Optibrium Ltd. 18 Sep 2025

Probiotic enhances cholesterol drug efficacy but raises safety concerns at high doses

A recent study published in Engineering has shed light on the complex interactions between probiotics and drugs, particularly focusing on the effects of the probiotic Lacticaseibacillus paracasei Zhang (LCZ) on the cholesterol-lowering drug lovastatin.

28 Aug 2025

Metformin lowers blood sugar by acting on brain pathways

Although metformin has been the go-to medication to manage type 2 diabetes for more than 60 years, researchers still do not have a complete picture of how it works.

31 Jul 2025

PFAS exposure may increase the risk of developing type 2 diabetes

Exposure to a class of synthetic chemicals known as per- and polyfluoroalkyl substances (PFAS)-often called "forever chemicals"-may increase the risk of developing type 2 diabetes, according to a new study led by Mount Sinai researchers.

22 Jul 2025

Vaginal microbiome fights back against stubborn BV infections

Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for personalized approaches to enhance efficacy.

3 Jul 2025

Optibrium partners with TalTech on EU-funded PhD program to advance sustainable drug discovery

Optibrium, a leading developer of software and AI solutions for molecular design, today announced its partnership with TalTech (Tallinn University of Technology) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.

2 Jul 2025

Study reveals sharp increase in global incidents of healthcare-related harm

The proportion of patient harms associated with medical procedures, treatment, and contact with healthcare systems rose by 59%, from 11 million to 18 million globally between 1990 and 2019, finds a data analysis published online in the journal BMJ Quality & Safety.

14 Jun 2025

How soy and gut microbes alter cancer treatment results

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes.

2 Jun 2025

Humanized liver organoids double survival rate in rodent models

One reason why our livers excel at clearing waste from our blood system is that the organ functions according to three key "zones" that perform specific major tasks.

16 Apr 2025

Can natural supplements backfire? Review explains how and why

A new review uncovers how common natural supplements can both protect and endanger health, depending on dose, duration, and delivery—and points to next-gen technologies as the key to unlocking their full therapeutic power.

31 Mar 2025

ELRIG announces Prof Rory Johnson and Dr Shalini Andersson as keynote speakers at Therapeutic Oligonucleotides 2025

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 14-15 May. Prof Rory Johnson, Associate Professor, University College Dublin, and Dr Shalini Andersson, Vice President Nucleic Acid Therapeutics, AstraZeneca will lead this year's event focused on 'drugging the undruggable'.

25 Mar 2025